Hydrocodone bitartrate and Homatropine methylbromide

Hydrocodone bitartrate and Homatropine methylbromide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Hydrocodone bitartrate and Homatropine methylbromide is an antitussive agent that is FDA approved for the treatment of cough. Common adverse reactions include constipation, nausea, vomiting, asthenia, dizziness, somnolence.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Cough

• For the symptomatic relief of cough.

• Dosing information

• Adults: One (1) teaspoonful (5 mL) every four to six hours as needed; do not exceed six (6) teaspoonfuls in 24 hours.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

• There is limited information regarding Off-Label Guideline-Supported Use of Hydrocodone bitartrate and Homatropine methylbromide in adult patients.

Non–Guideline-Supported Use

• There is limited information regarding Off-Label Non–Guideline-Supported Use of Hydrocodone bitartrate and Homatropine methylbromide in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Cough

• For the symptomatic relief of cough.

• Dosing information

• Children 6 to 12 years of age: One-half (½) teaspoonful (2.5 mL) every four to six hours as needed; do not exceed three (3) teaspoonfuls in 24 hours.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

• There is limited information regarding Off-Label Guideline-Supported Use of Hydrocodone bitartrate and Homatropine methylbromide in pediatric patients.

Non–Guideline-Supported Use

• There is limited information regarding Off-Label Non–Guideline-Supported Use of Hydrocodone bitartrate and Homatropine methylbromide in pediatric patients.

Contraindications

• Should not be administered to patients who are hypersensitive to hydrocodone or homatropine methylbromide.

Warnings

• May be habit forming. Hydrocodone can produce drug dependence of the morphine type and, therefore, has the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of hydrocodone bitartrate and homatropine methylbromide, and it should be prescribed and administered with the same degree of caution appropriate to the use of other narcotic drugs.

• Respiratory Depression: Hydrocodone produces dose-related respiratory depression by directly acting on brain stem respiratory centers. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.

• Head Injury and Increased Intracranial Pressure: The respiratory depression properties of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

• Acute Abdominal Conditions: The administration of hydrocodone or other narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

• Pediatric Use: In young pediatric patients, as well as adults, the respiratory center is sensitive to the depressant action of narcotic cough suppressants in a dose-dependent manner. Benefit to risk ratio should be carefully considered especially in pediatric patients with respiratory embarrassment (e.g., croup).

Precautions

General

• Before prescribing medication to suppress or modify cough, it is important to ascertain that the underlying cause of cough is identified, that modification of cough does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is provided.

• Special Risk Patients: Hydrocodone bitartrate and homatropine methylbromide should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, prostatic hypertrophy or urethral stricture, asthma, and narrow-angle glaucoma.

Adverse Reactions

Clinical Trials Experience

• Central Nervous System: Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes.

• Gastrointestinal System: Nausea and vomiting may occur; they are more frequent in ambulatory than in recumbent patients. Prolonged administration of hydrocodone bitartrate and homatropine methylbromide may produce constipation.

• Genitourinary System: Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.

• Respiratory Depression: Hydrocodone may produce dose-related respiratory depression by acting directly on brain stem respiratory centers.

• Dermatological: Skin rash, pruritus.

Drug abuse and dependence

• Hydrocodone bitartrate and homatropine methylbromide syrup is a Schedule II controlled substance. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, hydrocodone bitartrate and homatropine methylbromide should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when hydrocodone bitartrate and homatropine methylbromide is used for a short time for the treatment of cough. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy.

Postmarketing Experience

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Postmarketing Experience in the drug label.

Drug Interactions

• Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and homatropine methylbromide may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced. The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C Teratogenic Effects

• Pregnancy Category C. Animal reproduction studies have not been conducted with hydrocodone bitartrate and homatropine methylbromide. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydrocodone bitartrate and homatropine methylbromide should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects

• Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.

Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hydrocodone bitartrate and Homatropine methylbromide in women who are pregnant.

Labor and Delivery

• As with all narcotics, administration of hydrocodone bitartrate and homatropine methylbromide to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.

Nursing Mothers

• It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone bitartrate and homatropine methylbromide, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

• Safety and effectiveness of hydrocodone bitartrate and homatropine methylbromide in pediatric patients under six have not been established.

Geriatic Use

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide in geriatric settings.

Gender

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Hydrocodone bitartrate and Homatropine methylbromide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Hydrocodone bitartrate and Homatropine methylbromide in patients who are immunocompromised.

Administration and Monitoring

Administration

• Adults: One (1) teaspoonful (5 mL) every four to six hours as needed; do not exceed six (6) teaspoonfuls in 24 hours.

• Children 6 to 12 years of age: One-half (½) teaspoonful (2.5 mL) every four to six hours as needed; do not exceed three (3) teaspoonfuls in 24 hours.

Monitoring

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Hydrocodone bitartrate and Homatropine methylbromide and IV administrations.

Overdosage

• Signs and Symptoms: Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage apnea, circulatory collapse, cardiac arrest and death may occur. The ingestion of very large amounts of this product may, in addition, result in acute homatropine intoxication.

• Treatment: Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated, including treatment for anticholinergic drug intoxication. Gastric emptying may be useful in removing unabsorbed drug.

Pharmacology

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Pharmacology in the drug label.

Mechanism of Action

• Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce miosis, euphoria, physical and psychological dependence.

Structure

• This product contains hydrocodone (dihydrocodeinone) bitartrate, USP, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide, USP is included in a subtherapeutic amount to discourage deliberate overdosage. Each 5 mL (one teaspoonful) contains:

• Hydrocodone Bitartrate, USP ........................ 5 mg

• Homatropine Methylbromide, USP ............... 1.5 mg

• The hydrocodone component is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5), a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine, has a molecular weight of 494.490, and may be represented by the following structural formula:

0482c2a1-figure-01

• Homatropine methylbromide, USP is a 3α-hydroxy-8-methyl-1αH, 5αH-tropanium bromide mandelate; a white crystal or fine white crystalline powder, with a molecular weight of 370.28.

0482c2a1-figure-02

• Inactive Ingredients: artificial cherry flavor, anhydrous citric acid, D&C Red #33, FD&C Blue #1, FD&C Red #40, methylparaben, propylene glycol, purified water, saccharin sodium, sodium benzoate, sodium citrate dihydrate, sucrose.

Pharmacodynamics

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Pharmacodynamics in the drug label.

Pharmacokinetics

• Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 ± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 ± 0.3 hours and the half-life was determined to be 3.8 ± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-α- and 6-ß-hydroxymetabolites.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

• Studies of hydrocodone bitartrate and homatropine methylbromide in animals to evaluate the carcinogenic and mutagenic potential and the effect on fertility have not been conducted.

Clinical Studies

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Clinical Studies in the drug label.

How Supplied

• This preparation is a red colored, cherry flavored syrup containing 5 mg hydrocodone bitartrate, USP and 1.5 mg homatropine methylbromide, USP per 5 mL, and is available in one pint (473 mL) bottles.

Storage

• Store at controlled room temperature 15° to 30°C (59° to 86°F).

• Dispense in a tight, light-resistant container as defined in the USP.

• Oral prescription where permitted by State Law.

Images

Drug Images

{{#ask: Page Name::Hydrocodone bitartrate and Homatropine methylbromide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

File:Hydrocodone and homatropine label.png

{{#ask: Label Page::Hydrocodone bitartrate and Homatropine methylbromide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

• Hydrocodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this product should be cautioned accordingly.

Precautions with Alcohol

• Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and homatropine methylbromide may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.

Brand Names

Hycodan, Hydromet, Tussigon.

Look-Alike Drug Names

There is limited information regarding Hydrocodone bitartrate and Homatropine methylbromide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.